PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33099948-0	2020	Anticancer activity of Voacangine against human oral cancer cells is due to G2/M cell cycle arrest, ROS-mediated cell death and inhibition of PI3K/AKT signalling pathway.	Voacangine	23-33	AKT serine/threonine kinase 1	Homo sapiens	147-150
33099948-12	2020	Additionally, the anticancer effects of Voacangine on oral cancer cells were exerted through the inhibition of PI3K/AKT signaling cascade.	Voacangine	40-50	AKT serine/threonine kinase 1	Homo sapiens	116-119
32230857-0	2020	Identification and Validation of VEGFR2 Kinase as a Target of Voacangine by a Systematic Combination of DARTS and MSI.	Voacangine	62-72	kinase insert domain protein receptor	Mus musculus	33-39
32230857-4	2020	Using label-free voacangine, an antiangiogenic alkaloid molecule as the model natural compound, DARTS analysis revealed vascular endothelial growth factor receptor 2 (VEGFR2) as a target protein.	Voacangine	17-27	kinase insert domain protein receptor	Mus musculus	120-165
32230857-4	2020	Using label-free voacangine, an antiangiogenic alkaloid molecule as the model natural compound, DARTS analysis revealed vascular endothelial growth factor receptor 2 (VEGFR2) as a target protein.	Voacangine	17-27	kinase insert domain protein receptor	Mus musculus	167-173
27257769-0	2016	Pharmacokinetics of hERG Channel Blocking Voacangine in Wistar Rats Applying a Validated LC-ESI-MS/MS Method.	Voacangine	42-52	ETS transcription factor ERG	Homo sapiens	20-24
32230857-5	2020	Voacangine inhibits VEGFR2 kinase activity and its downstream signaling by binding to the kinase domain of VEGFR2, as was revealed by docking simulation.	Voacangine	0-10	kinase insert domain protein receptor	Mus musculus	20-26
32230857-5	2020	Voacangine inhibits VEGFR2 kinase activity and its downstream signaling by binding to the kinase domain of VEGFR2, as was revealed by docking simulation.	Voacangine	0-10	kinase insert domain protein receptor	Mus musculus	107-113
32230857-6	2020	Through cell culture assays, voacangine was found to inhibit the growth of glioblastoma cells expressing high levels of VEGFR2.	Voacangine	29-39	kinase insert domain protein receptor	Mus musculus	120-126
32230857-8	2020	The overlap of histological images with the MSI signals for voacangine was intense in the tumor regions and showed colocalization of voacangine and VEGFR2 in the tumor tissues by immunofluorescence analysis of VEGFR2.	Voacangine	60-70	kinase insert domain protein receptor	Mus musculus	148-154
32230857-8	2020	The overlap of histological images with the MSI signals for voacangine was intense in the tumor regions and showed colocalization of voacangine and VEGFR2 in the tumor tissues by immunofluorescence analysis of VEGFR2.	Voacangine	60-70	kinase insert domain protein receptor	Mus musculus	210-216
22155252-5	2012	Voacangine significantly suppressed in vitro angiogenesis, such as VEGF-induced tube formation and chemoinvasion.	Voacangine	0-10	vascular endothelial growth factor A	Homo sapiens	67-71
25052206-1	2014	The iboga alkaloid voacangine (1) has been reported previously to be the first stimulus-selective TRPM8 antagonist.	Voacangine	19-29	transient receptor potential cation channel subfamily M member 8	Homo sapiens	98-103
22155252-7	2012	In addition, voacangine decreased the expression levels of hypoxia inducible factor-1alpha and its target gene, VEGF, in a dose-dependent manner.	Voacangine	13-23	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-90
22155252-7	2012	In addition, voacangine decreased the expression levels of hypoxia inducible factor-1alpha and its target gene, VEGF, in a dose-dependent manner.	Voacangine	13-23	vascular endothelial growth factor A	Homo sapiens	112-116
34201900-10	2021	Moreover, voacangine (most effective virucidal agent) was also effective against one strain of DENV-1 (DENV-1/WestPac/74) and against the third strain of DENV-2 (DENV-2/S16803) (48.5% and 32.4% infection, respectively).	Voacangine	10-20	denv-1/westpac/74	None	103-120
34730352-4	2021	Among these Voa structure analogues, Voa analogue 19 (V19) exhibited increased antiangiogenic potency against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.	Voacangine	12-15	vascular endothelial growth factor A	Mus musculus	110-114
34730352-4	2021	Among these Voa structure analogues, Voa analogue 19 (V19) exhibited increased antiangiogenic potency against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.	Voacangine	12-15	kinase insert domain protein receptor	Mus musculus	123-129
34730352-4	2021	Among these Voa structure analogues, Voa analogue 19 (V19) exhibited increased antiangiogenic potency against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.	Voacangine	37-40	vascular endothelial growth factor A	Mus musculus	110-114
34730352-4	2021	Among these Voa structure analogues, Voa analogue 19 (V19) exhibited increased antiangiogenic potency against VEGF-induced VEGFR2 phosphorylation without cytotoxic effects.	Voacangine	37-40	kinase insert domain protein receptor	Mus musculus	123-129
34730352-6	2021	In conclusion, this new VEGFR2 modulator, inspired from the rigid scaffold of a natural compound, Voa, is presented as a potent candidate in the development of new antiangiogenic agents.	Voacangine	98-101	kinase insert domain protein receptor	Mus musculus	24-30